Notice2026-11519
Office of the Director; Notice of Charter Renewal
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
June 9, 2026
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Full Text
<html>
<head>
<title>Federal Register, Volume 91 Issue 110 (Tuesday, June 9, 2026)</title>
</head>
<body><pre>
[Federal Register Volume 91, Number 110 (Tuesday, June 9, 2026)]
[Notices]
[Pages 34829-34831]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2026-11519]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Office of the Director; Notice of Charter Renewal
In accordance with Title 41 of the U.S. Code of Federal
Regulations, Section 102-3.65(a), notice is hereby given that the
charter for the Clinical Center Research Hospital Board (CCRHB) is
being renewed for an additional two-year period on June 15, 2026.
It is determined that the CCRHB is in the public interest in
connection with the performance of duties imposed on the National
Institutes of Health by law, and that these duties can best be
performed through the advice and counsel of this group.
The Public Interest Determination follows:
National Institutes of Health
Clinical Center Research Hospital Board
Public Interest Determination
Pursuant to 41 CFR 102-3.60(a), to establish, renew, reestablish,
or merge a discretionary (agency discretion) advisory committee, an
agency must first consult with the General Services Administration's
Committee Management Secretariat (the Secretariat) and, as part of the
consultation, provide a written public interest determination approved
by the head of the agency to the Secretariat with a copy to the Office
of Management and Budget. In addition, pursuant to 41 CFR 102-3.35, an
agency shall follow the same consultation process and document in
writing the same determination of need before creating a subcommittee
under a discretionary committee that is not made up entirely of members
of a parent advisory committee.
Information on the following factors for the committee is provided
to the Secretariat to demonstrate that renewing the committee is in the
public interest:
1. Annual budget: The annual budget for the committee is $67,425.
a. Federal personnel on a full-time equivalent (FTE) basis: Federal
personnel (based on full-time equivalent (FTE) usage basis) and other
Federal internal costs. The estimated annual personal years of staff
support are .1 at an estimated cost of $15,709.
b. Other Federal internal costs: The estimated for other Federal
internal costs is 0.
c. Proposed payments to members: The estimated payment for non-
Federal members is $5,400. There are no Federal members on this
committee.
d. Proposed number of members: The Clinical Center Research
Hospital Board (CCRHB or Board) will consist of up to 14 non-federal
members, including the chair.
e. Reimbursable costs: The estimate for reimbursable costs,
including members' travel expenses is $41,548.
2. If applicable, the total dollar value of grants expected to be
recommended during the fiscal year: N/A.
3. Criteria for selecting members to ensure the committee has the
necessary expertise and fairly balanced membership:
The Board will consist of up to 14 non-federal members, including
the chair, appointed by the NIH Director (or delegee). The appointed
members will consist of (a) authorities who are nationally recognized
leaders in sectors related to the NIH Clinical Center's (CC) duties and
authorities, including but not limited to research hospital
administration/operations, clinical care, safety and quality, clinical
and research compliance, or clinical research, and (b) two individuals
who have participated in clinical research studies as patients.
Appointed members will be selected from the academic and private sector
research community, as well as the general public.
4. List of all other Federal advisory committees of the agency:
<bullet> Advisory Committee on Research on Women's Health
<bullet> Advisory Committee to the Director, National Institutes of
Health
<bullet> Advisory Council on Parkinson's Research, Care and Services
<bullet> Aging and Neurodegeneration Integrated Review Group
<bullet> AIDS Research Advisory Committee, NIAID
<bullet> Applied Immunology and Disease Control Integrated Review Group
[[Page 34830]]
<bullet> Applied Therapeutics for Cancer Integrated Review Group
<bullet> Biobehavioral and Behavioral Processes Integrated Review Group
<bullet> Bioengineering Sciences & Technologies Integrated Review Group
<bullet> Biological Chemistry and Macromolecular Biophysics Integrated
Review Group
<bullet> Board of Regents of the National Library of Medicine
<bullet> Board of Scientific Counselors Eunice Kennedy Shriver National
Institute of Child Health and Human Development
<bullet> Board of Scientific Counselors National Human Genome Research
Institute
<bullet> Board of Scientific Counselors of the National Heart, Lung,
and Blood Institute
<bullet> Board of Scientific Counselors of the NIH Clinical Center
<bullet> Board of Scientific Counselors, Division of Translational
Toxicology
<bullet> Board of Scientific Counselors, National Cancer Institute
<bullet> Board of Scientific Counselors, National Center for
Complementary and Integrative Health
<bullet> Board of Scientific Counselors, National Eye Institute
<bullet> Board of Scientific Counselors, National Institute of
Arthritis and Musculoskeletal and Skin Diseases
<bullet> Board of Scientific Counselors, National Institute of
Biomedical Imaging and Bioengineering
<bullet> Board of Scientific Counselors, National Institute of Dental
and Craniofacial Research
<bullet> Board of Scientific Counselors, National Institute of Diabetes
and Digestive and Kidney Diseases
<bullet> Board of Scientific Counselors, National Institute of
Environmental Health Sciences
<bullet> Board of Scientific Counselors, National Institute of Mental
Health
<bullet> Board of Scientific Counselors, National Institute of
Neurological Disorders and Stroke
<bullet> Board of Scientific Counselors, National Institute on Aging
<bullet> Board of Scientific Counselors, National Institute on Alcohol
Abuse and Alcoholism
<bullet> Board of Scientific Counselors, National Institute on Deafness
and Other Communication Disorders
<bullet> Board of Scientific Counselors, National Institute on Drug
Abuse
<bullet> Board of Scientific Counselors, National Institute on Minority
Health and Health Disparities and National Institute of Nursing
Research
<bullet> Board of Scientific Counselors, National Library of Medicine
<bullet> Brain Disorders and Clinical Neuroscience Integrated Review
Group
<bullet> Cardiovascular and Respiratory Sciences Integrated Review
Group
<bullet> Cell Biology Integrated Review Group
<bullet> Center for Scientific Review Special Emphasis Panel
<bullet> Council of Councils
<bullet> Cures Acceleration Network Review Board
<bullet> Digestive, Kidney and Urological Systems Integrated Review
Group
<bullet> Division of Intramural Research Board of Scientific Counselors
National Institute of Allergy and Infectious Diseases
<bullet> Emerging Technologies and Training Neurosciences Integrated
Review Group
<bullet> Endocrinology, Metabolism, Nutrition and Reproductive Sciences
Integrated Review Group
<bullet> Fogarty International Center Advisory Board
<bullet> Genes, Genomes, and Genetics Integrated Review Group
<bullet> Healthcare Delivery and Methodologies Integrated Review Group
<bullet> Infectious Diseases and Immunology A Integrated Review Group
<bullet> Infectious Diseases and Immunology B Integrated Review Group
<bullet> Integrative, Functional and Cognitive Neuroscience Integrated
Review Group
<bullet> Interagency Autism Coordinating Committee
<bullet> Interagency Pain Research Coordinating Committee
<bullet> Interdisciplinary Molecular Sciences and Training Integrated
Review Group
<bullet> Molecular, Cellular and Developmental Neuroscience Integrated
Review Group
<bullet> Muscular Dystrophy Coordinating Committee
<bullet> Musculoskeletal, Oral, and Skin Sciences Integrated Review
Group
<bullet> National Advisory Allergy and Infectious Diseases Council
<bullet> National Advisory Board on Medical Rehabilitation Research
<bullet> National Advisory Child Health and Human Development Council
<bullet> National Advisory Council for Biomedical Imaging and
Bioengineering
<bullet> National Advisory Council for Complementary and Integrative
Health
<bullet> National Advisory Council for Human Genome Research
<bullet> National Advisory Council for Nursing Research
<bullet> National Advisory Council on Aging
<bullet> National Advisory Council on Alcohol Abuse and Alcoholism
<bullet> National Advisory Council on Drug Abuse
<bullet> National Advisory Council on Minority Health and Health
Disparities
<bullet> National Advisory Dental and Craniofacial Research Council
<bullet> National Advisory Environmental Health Sciences Council
<bullet> National Advisory Eye Council
<bullet> National Advisory General Medical Sciences Council
<bullet> National Advisory Mental Health Council
<bullet> National Advisory Neurological Disorders and Stroke Council
<bullet> National Arthritis and Musculoskeletal and Skin Diseases
Advisory Council
<bullet> National Cancer Advisory Board
<bullet> National Cancer Institute Clinical Trials and Translational
Research Advisory Committee
<bullet> National Cancer Institute Council of Research Advocates
<bullet> National Center for Advancing Translational Sciences Advisory
Council
<bullet> National Deafness and Other Communication Disorders Advisory
Council
<bullet> National Diabetes and Digestive and Kidney Diseases Advisory
Council
<bullet> National Heart, Lung, and Blood Advisory Council
<bullet> National Science Advisory Board for Biosecurity
<bullet> National Toxicology Program Board of Scientific Counselors
<bullet> National Toxicology Program Special Emphasis Panel
<bullet> NIH Clinical Center Research Hospital Board
<bullet> Office of AIDS Research Advisory Council
<bullet> Office of Research Infrastructure Programs Special Emphasis
Panel
<bullet> Oncology 1-Basic Translational Integrated Review Group
<bullet> Oncology 2-Translational Clinical Integrated Review Group
<bullet> Population Sciences and Epidemiology Integrated Review Group
<bullet> President's Cancer Panel
<bullet> Risk, Prevention and Health Behavior Integrated Review Group
<bullet> Scientific Advisory Committee on Alternative Toxicological
Methods
<bullet> Scientific and Technical Review Board on Biomedical and
Behavioral Research Facilities
<bullet> Scientific Management Review Board
<bullet> Sickle Cell Disease Advisory Committee
<bullet> Sleep Disorders Research Advisory Board
<bullet> Social and Community Influences on Health Integrated Review
Group
[[Page 34831]]
<bullet> Surgical Sciences, Biomedical Imaging and Bioengineering
Integrated Review Group
<bullet> Vaccine Research Center Board of Scientific Counselors
National Institute of Allergy and Infectious Diseases
<bullet> Vascular and Hematology Integrated Review Group
5. Justification that the information or advice provided by the
Federal advisory committee or subcommittee is not available from
another Federal advisory committee, another Federal Government source,
or any other more cost-effective and less burdensome source:
All members of the CCRHB are directly or indirectly associated with
biomedical research, and upon acceptance of CCRHB appointment, each
member is fully introduced to the unique aspects of the CC hospital
which exists to provide safe delivery of patient-centric care in
support of scientific research aligned with public health needs. Each
year approximately 10,000 new research participants are seen at the CC
as active partners in medical discovery, a partnership that has
resulted in a long list of medical milestones, including the first cure
of a solid tumor with chemotherapy, gene therapy, and the use of AZT to
treat AIDS. The CC differs from other hospitals as it is not a general
hospital, nor is it a part of a health system. There is no trauma care,
no emergency room, no labor and delivery and no billing department. The
mission of the CC is to provide hope through pioneering clinical
research to improve human health. With our patient partners, the CC
proudly is referenced as the ``House of Hope.'' The Board members'
recommendations are invaluable because the complex nature of the CC's
clinical research mission requires a unique balance and breadth of
expertise not available at NIH or from other established sources. This
advice and unique, expert perspectives cannot be obtained through other
mechanisms.
6. If the consultation is a committee renewal, a summary of the
previous accomplishments of the committee and the reasons it needs to
continue:
The CCRHB is the sole entity to provide advice about hospital
operations aligned with the CC's clinical research priorities. As such,
the CCRHB's focus is on the complementary aims of achieving the highest
standards of safety for research participants and the CC community,
while fostering an environment of cutting-edge high-impact research to
improve the health of Americans.
2016: The CCRHB recommended the submission of regular reports to
the Board addressing Patient Safety & Quality Performance Metrics. This
topic became a `standing item' for all Board meetings and members
continue to receive a Current Executive Dashboard Report on Clinical
and Safety Performance Metrics one week prior to each meeting for
review. The CEO Presentation includes reference to these standing
reports; and the CEO solicits discussion or questions from the Board,
then reports are posted on the CC's website for public review.
2016--Present: Annual reports to the CCRHB are delivered by the
Director, Office of Research Facilities. These reports generate
discussions for planned or ongoing facility changes that directly or
indirectly affect CC patients, researchers, staff, and the CC
community. In October 2019, all Board members signed a letter to the
NIH Director, ultimately shared with Congress during budget
discussions, to address needed funding for NIH maintenance issues and
facility projects to improve environment of care and specialized
capabilities requests, including construction of the new Surgery,
Radiology and Laboratory Medicine Wing.
A key accomplishment of the CCRHB in 2022 was to provide a
comprehensive review and assessment of pediatric care at the CC,
focused on the delivery of care to children, current clinical research
studies, and setting a vision to consider for the future of pediatric
research. With the assistance of a working group that included
pediatric leaders from across the country, the CCRHB provided advice
that identified strengths and areas of focused improvement to be
considered going forward.
7. Explanation of why the committee/subcommittee is essential to
the conduct of agency business:
The CCRHB was created in 2016 as recommended by the Advisory
Committee to the NIH Director following results of an FDA visit and
review of hospital operations. Per the CCRHB charter, the purpose of
the Board is to advise, consult with, and make recommendations to the
NIH Principal Deputy Director (or designee) and the CEO with respect to
maintaining excellence in hospital operations, safety and quality,
unique clinical research care requirements for CC patients, regulatory
compliance, clinical research, and hospital leadership performance
oversight. Currently in its 9th year, the CCRHB has provided expert
guidance and recommendations related to most aspects of CC operations.
In conclusion, this public interest determination documents that
renewing the committee is in the public interest, essential to the
conduct of agency business, and that the information to be obtained is
not already available through another advisory committee or source
within the Federal Government.
Inquiries may be directed to Patricia Brandt Hansberger, Acting
Director, Office of Federal Advisory Committee Policy, Office of the
Director, National Institutes of Health, 6701 Democracy Boulevard,
Suite 1000, Bethesda, Maryland 20892 (Mail code 4875), Telephone (301)
496-2123, or <a href="/cdn-cgi/l/email-protection#fc8c9d888e959f959dd2949d928f9e998e9b998ebc929594d29b938a"><span class="__cf_email__" data-cfemail="67170613150e040e06490f06091405021500021527090e0f49000811">[email protected]</span></a>.
Dated: June 3, 2026.
Denise M. Santeufemio,
Supervisory Program Analyst, Office of Federal Advisory Committee
Policy.
[FR Doc. 2026-11519 Filed 6-5-26; 4:15 pm]
BILLING CODE 4167-05-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on June 9, 2026.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.